Emcure expands injectables capacity, opens 3rd facility in Gujarat
时间:2024-06-26 14:10:51 阅读(143)
The third injectable facility of Emcure Pharmaceuticals in Mehsana, Gujarat, which was commissioned in August 2023, is now ready for commercial supplies to domestic and international markets. The company already has an oral formulations manufacturing line in Mehsana.
It also has a facility in Hinjawadi, Pune, with a capacity of 80.64 million vials per annum and another in Sanand, Gujarat, with a capacity to churn out 72 million vials per annum.
IPO-bound Emcure’s manufacturing operations cover oral solids, oral liquids and injectables, including liposomal and lyophilized injectables, biotherapeutics and complex APIs. The company’s subsidiary Gennova Biopharmaceuticals,also plans to use its mRNA platform, through which it launched the Covid-19 vaccine, forthree other vaccines for Zoster, Zika and Rabies.
Emcure’s injectable portfolio includes complex iron injectables, oncology, steroids, suspensions and emulsions. Emcure can produce high-potency injectables, particularly oncology products.
Emcure had filed a draft red herring prospectus (DRHP) on December 16 for its Rs 800 crore IPO. It is the 12th largest Indian pharmaceutical company and the largest pharmaceutical company in the gynaecology, blood-related and HIV antiviral therapeutics segment in the country.
For the international markets, the firm’s focus is on developing and commercialising products, which requires significant expertise and is subject to less competition and offers higher margins.
In Europe and other key target markets, they are focused on higher-value-added generics and complex injectables, such as Cidofovir and Meropenem. Europe is one of the focus areas in the hospital segment, as it is a large market for complex injectables products, such as Cidofovir, BiCNU and Treprostinil, the company’s DRHP said.
The company is working on `ready-to-use’ products that reduce multi-step dose preparation and enable ease of use by physicians.
猜你喜欢
- Bata India shares spike 6% on Adidas partnership speculations
- Tata Motors Rating- Buy - Disappointing qtr; focus shifts to Q4
- Saint-Gobain lines up investments across biz segments in Tamil Nadu
- Saint-Gobain lines up investments across biz segments in Tamil Nadu
- Rupee trades flat at 83
- Tata Consumer Products Rating- add; A good fit in Tata Consumer portfolio
- Tamilnad Mercantile Bank IPO share listing today- Flat listing on BSE, NSE; stock debuts at Rs 510 per share
- Rupee likely to remain steady amid strong dollar, risk aversion in markets; USDINR pair to trade sideways
- Tata Motors- Q3 margins improve across segments